Post-earnings recap
Reported
Tue, Nov 5, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Arcus Biosciences saw a positive stock reaction, rising 3.85%. This increase may be attributed to management's optimistic outlook on their clinical trials and pipeline developments. Investors may be encouraged by the potential for future data releases, even without specific guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Overall, management expressed optimism about their pipeline and the potential for future developments. They noted the significance of their ongoing studies.
Management highlighted ongoing progress in clinical trials.
They emphasized the importance of upcoming data releases.